

Retraction for Liaki et al., A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance

Retraction for “A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance,” by Vasiliki Liaki, Sara Barrambana, Myrto Kostopoulou, Carmen G. Lechuga, Elena Zamorano-Dominguez, Domingo Acosta, Lucia Morales-Cacho, Ruth Álvarez, Pian Sun, Blanca Rosas-Perez, Rebeca Barrero, Silvia Jiménez-Parrado, Alejandra López-García, Marta San Roman, Juan Carlos López-Gil, Matthias Drostén, Bruno Sainz Jr., Monica Musteanu, Eduardo Caleiras, Nelson Dusetti, Valeria Poli, Francisco Sánchez-Bueno, Carmen Guerra, and Mariano Barbacid, which published December 2, 2025; 10.1073/pnas.2523039122 (*Proc. Natl. Acad. Sci. U.S.A.* **122**, e2523039122).

The editors are retracting this article due to an undisclosed relevant competing interest at the time of submission. NAS Member Contributing author, Mariano Barbacid, and two coauthors, Vasiliki Liaki and Carmen Guerra, hold financial interests in Vega Oncotargets.

PNAS editorial policy for Contributed submissions provides that “Academy members who have a competing interest, financial or otherwise, that could be seen as significantly influencing their objectivity or as creating an unfair competitive advantage for any person or organization tied to the research should submit their work as a Direct Submission.”

This article is distributed under [Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 \(CC BY-NC-ND\)](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Published April 27, 2026.